Get the Stockscreener App
95.90
0.83%
-0.80
After Hours:
95.90
Boston Scientific Corp stock is traded at $95.90, with a volume of 8.18M.
It is down -0.83% in the last 24 hours and down -10.56% over the past month.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
See More
Previous Close:
$96.70
Open:
$96.56
24h Volume:
8.18M
Relative Volume:
1.00
Market Cap:
$142.10B
Revenue:
$18.49B
Net Income/Loss:
$2.50B
P/E Ratio:
57.08
EPS:
1.6801
Net Cash Flow:
$3.49B
1W Performance:
-1.77%
1M Performance:
-10.56%
6M Performance:
+4.76%
1Y Performance:
+13.61%
1-Day Range:
$95.38
$96.73
1-Week Range:
$90.69
$99.01
52-Week Range:
$80.64
$109.50
Boston Scientific Corp Stock (BSX) Company Profile
Name
Boston Scientific Corp
Sector
Industry
Phone
508-683-4000
Address
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Compare BSX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
95.90 | 143.29B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
ABT
Abbott Laboratories
|
133.02 | 232.77B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
SYK
Stryker Corp
|
369.24 | 140.03B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
98.33 | 126.25B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
76.72 | 44.95B | 5.69B | 1.41B | 577.90M | 6.9828 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-03-25 | Downgrade | Erste Group | Buy → Hold |
| Sep-08-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-16-25 | Initiated | Leerink Partners | Outperform |
| Apr-16-25 | Upgrade | Needham | Hold → Buy |
| Jan-10-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Oct-18-24 | Downgrade | Needham | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Feb-01-24 | Upgrade | Mizuho | Neutral → Buy |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Jun-30-23 | Initiated | CL King | Buy |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Buy |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-20-22 | Resumed | Citigroup | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-06-22 | Initiated | Wolfe Research | Outperform |
| May-27-22 | Upgrade | Needham | Hold → Buy |
| Apr-13-22 | Resumed | Truist | Buy |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| May-26-21 | Downgrade | Needham | Buy → Hold |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Sep-17-20 | Initiated | Truist | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Peer Perform |
| Apr-22-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-01-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Buy |
| Dec-30-19 | Reiterated | Cowen | Outperform |
| Dec-19-19 | Downgrade | Needham | Strong Buy → Buy |
| Sep-05-19 | Resumed | JP Morgan | Overweight |
| Sep-03-19 | Resumed | Barclays | Overweight |
| May-13-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-28-18 | Initiated | UBS | Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Oct-02-18 | Reiterated | Morgan Stanley | Overweight |
| Sep-07-18 | Reiterated | Needham | Strong Buy |
| Sep-04-18 | Upgrade | Jefferies | Hold → Buy |
| Jul-06-18 | Reiterated | Needham | Strong Buy |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Apr-26-18 | Reiterated | Needham | Strong Buy |
View All
Boston Scientific Corp Stock (BSX) Latest News
Boston Scientific (BSX) Target Price Cut by Evercore ISI Amid Ma - GuruFocus
Boston Scientific (BSX): Evaluating Valuation as Analyst Confidence Remains High Following Strong Segment Growth and Innovation - simplywall.st
What You Need To Know Ahead Of Boston Scientific's Earnings Release - Barchart.com
Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term - Yahoo Finance
Using data tools to time your Boston Scientific Corporation exitMarket Trend Report & Weekly Stock Breakout Alerts - newser.com
Why Boston Scientific Corporation stock remains on watchlists2025 Geopolitical Influence & Low Risk Entry Point Tips - newser.com
Is Boston Scientific’s Innovation Push in Endoscopy at MEDevice Boston a Sign of R&D Leadership (BSX)? - Yahoo Finance
How Are Analysts Weighing Boston Scientific’s (BSX) Innovation Pipeline Against Market Execution Strategies? - simplywall.st
Boston Scientific stock rating reiterated at Overweight by Piper Sandler - Investing.com
The Zacks Analyst Blog Highlights Boston Scientific, Union Pacific, Realty Income and Weyco - sharewise.com
Boston Scientific stock rating downgraded to Hold by Erste Group - Investing.com
RBC Capital Maintains a Buy on Boston Scientific Corporation (BSX) With a $125 PT - Insider Monkey
How Boston Scientific Corporation stock benefits from digital adoptionEarnings Risk Report & Detailed Earnings Play Alerts - newser.com
Top Research Reports for Boston Scientific, Union Pacific & Realty Income - Yahoo Finance
Leerink Partners Reaffirms Their Buy Rating on Boston Scientific (BSX) - The Globe and Mail
Truist Financial Sticks to Their Buy Rating for Boston Scientific (BSX) - The Globe and Mail
Boston Scientific aims for market leadership in electrophysiology - Yahoo Finance
Boston Scientific (NYSE:BSX) Receives “Buy” Rating from Needham & Company LLC - Defense World
Boston Scientific (NYSE:BSX) Price Target Raised to $129.00 at Truist Financial - Defense World
Boston Scientific (BSX) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Boston Sci closes Elutia deal, projects 10% growth through 2028 - BioWorld MedTech
Oppenheimer reiterates Outperform rating on Boston Scientific stock By Investing.com - Investing.com Nigeria
Boston Scientific (BSX) Analyst Rating Update: Canaccord Genuity Raises Price Target | BSX Stock News - GuruFocus
Elutia Announces Closing Of Bioenvelope Business Sale To Boston Scientific Corporation - TradingView
What consensus target says about Boston Scientific Corporation stock2025 Biggest Moves & Verified Entry Point Detection - newser.com
Baird Raises Price Target for Boston Scientific (BSX) to $128.00 - GuruFocus
Boston Scientific stock outlook positive as TD Cowen reiterates buy rating - Investing.com
Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million - The Manila Times
Boston Scientific stock rating reiterated at Outperform by RBC Capital - Investing.com
Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million - Benzinga
Vaginal Mesh Lawsuit Settlements | October 2025 Updates - Lawsuit Information Center
Boston Scientific To Rally More Than 35%? Here Are 10 Top Analyst Forecasts For Wednesday - inkl
Boston Scientific stock gets Outperform rating from Bernstein on growth outlook - Investing.com
Oppenheimer reiterates Outperform rating on Boston Scientific stock - Investing.com
Boston Scientific (BSX): Analyst Mike Matson Reiterates Buy Rati - GuruFocus
Boston Scientific unveils plans for new Watchman device - Yahoo Finance
Boston Scientific’s Promising Growth Trajectory: Buy Rating Supported by Innovative Products and Strategic Expansion - TipRanks
Canaccord Genuity raises Boston Scientific stock price target on growth outlook - Investing.com
Boston Scientific stock price target raised to $132 at BTIG on growth outlook - Investing.com
Piper Sandler Reaffirms its Overweight Rating and $115 Price Target on Boston Scientific Corporation (BSX) - Insider Monkey
Union Bancaire Privee UBP SA Lowers Position in Boston Scientific Corporation $BSX - MarketBeat
RBC Capital Keeps Their Buy Rating on Boston Scientific (BSX) - The Globe and Mail
Neurotech Devices Market Is Booming Worldwide 2025-2032 | Boston Scientific Corporation and BrainCo, Inc. - openPR.com
Boston Scientific stock outlook remains strong as RBC reiterates rating - Investing.com
Generate Investment Management Ltd Reduces Stock Holdings in Boston Scientific Corporation $BSX - MarketBeat
Order flow analysis tools used on Boston Scientific CorporationJuly 2025 EndofMonth & Accurate Entry/Exit Alerts - newser.com
Western Financial Corp CA Buys 9,465 Shares of Boston Scientific Corporation $BSX - MarketBeat
AAFMAA Wealth Management & Trust LLC Sells 7,118 Shares of Boston Scientific Corporation $BSX - MarketBeat
Accurate Wealth Management LLC Sells 27,611 Shares of Boston Scientific Corporation $BSX - MarketBeat
Why this $8-billion money manager likes Boston Scientific and Oracle - The Globe and Mail
November 7th Options Now Available For Boston Scientific (BSX) - Nasdaq
Boston Scientific Corp Stock (BSX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.81%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):